Precigen
PGEN----
Precigen (PGEN)
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Precigen Analyst Rating
View MoreForecast & Rating
Jul 27, 2026Price forecast
$12.50130.63%
Forecast & RatingBuy
3analysts
- Strong buy33.33%
- Buy33.33%
- Hold33.33%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 21 at 07:03 AM
Precigen schedules Q2 financial results conference call
- Simplywall · Jul 9 at 02:57 PM
Precigen (PGEN) In Focus As Russell Removal Tests Its Undervalued Narrative
- PUBT · Jul 1 at 05:20 PM
Precigen CEO Helen Sabzevari disposes of 346,836 common shares worth $2,042,858.04
- PUBT · Jun 24 at 03:08 PM
Precigen shareholders approve 7 million-share increase to 2023 incentive plan at annual meeting
- Market Beat · Jun 16 at 05:39 AM
Precigen, Inc. $PGEN Holdings Increased by Occam Crest Management LP
- StockTitan · Jun 14 at 09:40 PM
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging | PGEN Stock News
